Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

The effects of mitragynine and morphine on schedule-controlled responding and antinociception in rats
Takato Hiranita, Francisco León, Jasmine S. Felix, et al.
Psychopharmacology (2019) Vol. 236, Iss. 9, pp. 2725-2734
Open Access | Times Cited: 45

Showing 1-25 of 45 citing articles:

Investigation of the Adrenergic and Opioid Binding Affinities, Metabolic Stability, Plasma Protein Binding Properties, and Functional Effects of Selected Indole-Based Kratom Alkaloids
Samuel Obeng, Shyam H. Kamble, Morgan E. Reeves, et al.
Journal of Medicinal Chemistry (2019) Vol. 63, Iss. 1, pp. 433-439
Open Access | Times Cited: 119
Patterns and reasons for kratom (Mitragyna speciosa) use among current and former opioid poly-drug users
Darshan Singh, Nelson Jeng‐Yeou Chear, Suresh Narayanan, et al.
Journal of Ethnopharmacology (2019) Vol. 249, pp. 112462-112462
Closed Access | Times Cited: 79
Pharmacological Comparison of Mitragynine and 7-Hydroxymitragynine: In Vitro Affinity and Efficacy forμ-Opioid Receptor and Opioid-Like Behavioral Effects in Rats
Samuel Obeng, Jenny L. Wilkerson, Francisco León, et al.
Journal of Pharmacology and Experimental Therapeutics (2020) Vol. 376, Iss. 3, pp. 410-427
Open Access | Times Cited: 77
Therapeutic benefit with caveats?: Analyzing social media data to understand the complexities of kratom use
Kirsten E. Smith, Jeffrey M. Rogers, Destiny Schriefer, et al.
Drug and Alcohol Dependence (2021) Vol. 226, pp. 108879-108879
Open Access | Times Cited: 56
Understanding Kratom Use: A Guide for Healthcare Providers
Marc T. Swogger, Kirsten E. Smith, Albert Garcia‐Romeu, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 52
Mitragynine Attenuates Morphine Withdrawal Effects in Rats—A Comparison With Methadone and Buprenorphine
Rahimah Hassan, Pike-See Cheah, Sreenivasan Sasidharan, et al.
Frontiers in Psychiatry (2020) Vol. 11
Open Access | Times Cited: 61
Natural Products for the Treatment of Pain: Chemistry and Pharmacology of Salvinorin A, Mitragynine, and Collybolide
Soumen Chakraborty, Susruta Majumdar
Biochemistry (2020) Vol. 60, Iss. 18, pp. 1381-1400
Open Access | Times Cited: 60
Lyophilized Kratom Tea as a Therapeutic Option for Opioid Dependence
Lisa Wilson, Hannah M. Harris, Shainnel O. Eans, et al.
Drug and Alcohol Dependence (2020) Vol. 216, pp. 108310-108310
Closed Access | Times Cited: 52
Activity of Mitragyna speciosa (“Kratom”) Alkaloids at Serotonin Receptors
Francisco León, Samuel Obeng, Marco Mottinelli, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13510-13523
Open Access | Times Cited: 51
A Novel Mitragynine Analog with Low-Efficacy Mu Opioid Receptor Agonism Displays Antinociception with Attenuated Adverse Effects
Soumen Chakraborty, Jeffrey F. DiBerto, Abdelfattah Faouzi, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 18, pp. 13873-13892
Open Access | Times Cited: 50
Kratom Alkaloids, Natural and Semi-Synthetic, Show Less Physical Dependence and Ameliorate Opioid Withdrawal
Lisa Wilson, Soumen Chakraborty, Shainnel O. Eans, et al.
Cellular and Molecular Neurobiology (2021) Vol. 41, Iss. 5, pp. 1131-1143
Open Access | Times Cited: 48
Oxidative Metabolism as a Modulator of Kratom’s Biological Actions
Soumen Chakraborty, Rajendra Uprety, Samuel T. Slocum, et al.
Journal of Medicinal Chemistry (2021) Vol. 64, Iss. 22, pp. 16553-16572
Open Access | Times Cited: 43
Searching for a Signal: Self-Reported Kratom Dose-Effect Relationships Among a Sample of US Adults With Regular Kratom Use Histories
Kirsten E. Smith, Jeffrey M. Rogers, Kelly E. Dunn, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 36
Social, psychological, and substance use characteristics of U.S. adults who use kratom: Initial findings from an online, crowdsourced study.
Kirsten E. Smith, Kelly E. Dunn, Oliver Grundmann, et al.
Experimental and Clinical Psychopharmacology (2021) Vol. 30, Iss. 6, pp. 983-996
Open Access | Times Cited: 40
Kratom Abuse Potential 2021: An Updated Eight Factor Analysis
Jack E. Henningfield, Daniel W. Wang, Marilyn A. Huestis
Frontiers in Pharmacology (2022) Vol. 12
Open Access | Times Cited: 26
In vitro and in vivo pharmacology of kratom
Takato Hiranita, Samuel Obeng, Abhisheak Sharma, et al.
Advances in pharmacology (2022), pp. 35-76
Closed Access | Times Cited: 23
Kratom instrumentalization for severe pain self-treatment resulting in addiction – A case report of acute and chronic subjective effects
Elisabeth Müller, Thomas Hillemacher, Christian P. Müller
Heliyon (2020) Vol. 6, Iss. 7, pp. e04507-e04507
Open Access | Times Cited: 33
A systematic review of (pre)clinical studies on the therapeutic potential and safety profile of kratom in humans
Elisabeth Prevete, Kim P. C. Kuypers, Eef L. Theunissen, et al.
Human Psychopharmacology Clinical and Experimental (2021) Vol. 37, Iss. 1
Open Access | Times Cited: 32
Kratom Alkaloids as Probes for Opioid Receptor Function: Pharmacological Characterization of Minor Indole and Oxindole Alkaloids from Kratom
Soumen Chakraborty, Rajendra Uprety, Amal EI Daibani, et al.
ACS Chemical Neuroscience (2021) Vol. 12, Iss. 14, pp. 2661-2678
Open Access | Times Cited: 28
Kratom: History, pharmacology, current user trends, adverse health effects and potential benefits
Oliver Grundmann, Robert G. Hendrickson, Michael I. Greenberg
Disease-a-Month (2022) Vol. 69, Iss. 6, pp. 101442-101442
Closed Access | Times Cited: 20
Interactive Effects ofµ-Opioid and Adrenergic-α2Receptor Agonists in Rats: Pharmacological Investigation of the Primary Kratom Alkaloid Mitragynine and Its Metabolite 7-Hydroxymitragynine
Samuel Obeng, Francisco León, Avi Patel, et al.
Journal of Pharmacology and Experimental Therapeutics (2022) Vol. 383, Iss. 3, pp. 182-198
Open Access | Times Cited: 19
Cannabidiol and mitragynine exhibit differential interactive effects in the attenuation of paclitaxel-induced mechanical allodynia, acute antinociception, and schedule-controlled responding in mice
Yuma T. Ortiz, Joshua A. Bilbrey, Jasmine S. Felix, et al.
Pharmacological Reports (2023) Vol. 75, Iss. 4, pp. 937-950
Closed Access | Times Cited: 11
A review on multi-therapeutic potential of the Mitragyna speciosa (kratom) alkaloids mitragynine and 7-hydroxymitragynine: experimental evidence and future perspectives
Taslima Begum, Mohd Hafiz Arzmi, Murni Nazira Sarian, et al.
Kuwait Journal of Science (2025), pp. 100381-100381
Open Access
Assessing physiological dependence and withdrawal potential of mitragynine using schedule-controlled behaviour in rats
Norsyifa Harun, Illa Syafiqah Johari, Sharif Mahsufi Mansor, et al.
Psychopharmacology (2019) Vol. 237, Iss. 3, pp. 855-867
Closed Access | Times Cited: 34
Kratom Use in the US: Both a Regional Phenomenon and a White Middle-Class Phenomenon? Evidence From NSDUH 2019 and an Online Convenience Sample
Jeffrey M. Rogers, Kirsten E. Smith, Justin C. Strickland, et al.
Frontiers in Pharmacology (2021) Vol. 12
Open Access | Times Cited: 25
Page 1 - Next Page

Scroll to top